The most recent NVIDIA BioNeMo foundation models can help drug discovery groups design drug molecules virtually. [Credit: NVIDIA]
NVIDIA is putting the power of generative AI for drug discovery into the hands of more pharmaceutical and biotech companies with an expanded collection of AI models and flexible deployment options. More than 100 firms are already using the company’s biomolecular BioNeMo platform to accelerate the development of therapeutics.“For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible,” said Kimberly Powell, NVIDIA VP of healthcare, in a press briefing. “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”
The latest additions to BioNeMo, announced today at NVIDIA G…